Q2 FY '21 report Jan 21 was Wed 27th Jan and signalled the rise...

Q2 FY '21 report Jan 21 was Wed 27th Jan and signalled the rise to the consolidation (?) pattern we are in today.
I'd be very surprised if Q2 FY '22 isn't significantly more price sensitive. (Monday 31st?)

From last year.

Race pivots to capitalise on the FTO via the new “Three Pillar” strategy
The December 2020 quarter (Q2 FY21) was highlighted by release of Race’s “Three Pillar”
strategic plan. Three Pillars informs Race’s tactical implementation of clinical programs to
demonstrate expanded efficacy and utility of Bisantrene across targeted indications, so
maximizing the potential of a downstream license or corporate sale to a scaled pharmaceutical
company.
The revised strategy was guided by a combination of impressive clinical data and Race’s
interest in further investigating the independent City of Hope pre-clinical observations that
Bisantrene is a potent inhibitor of FTO (Fat mass and Obesity-associated protein).